文献简介

出版社:Adis, Springer International

作  者:Dene Simpson and Katherine A. Lyseng-Williamson

编  号:

关键字:

年  份:2006   点击量:819

文献摘要

Famciclovir (Famvir) is the oral prodrug of penciclovir, an agent that has demonstrated antiviral activity against herpes simplex viruses, type 1 (HSV-1) and 2 (HSV-2) [which cause orolabial and/or genital herpes simplex], and against varicella zoster virus (VZV) [a reactivation of which leads to herpes zoster].

泛昔洛韦(泛昔洛韦片)是喷昔洛韦口服前体药物,且经研究证明该药物对单纯疱疹病毒1型(HSV-1)和2型(HSV-2[可引起口唇、生殖器疱疹]以及水痘带状疱疹病毒(VZV[该病毒激活可导致带状疱疹] 有抗病毒活性。

Famciclovir has efficacy similar to that of aciclovir (in immunocompetent or immunocompromised patients) or valaciclovir (in immunocompetent patients) in the treatment of herpes zoster, and efficacy similar to aciclovir in the treatment of first or recurrent episodes of genital herpes (in immunocompetent or immunocompromised patients). Famciclovir also has efficacy in the suppression of recurrent episodes of genital herpes, and in the treatment of orolabial herpes, in immunocompetent patients.

泛昔洛韦与阿昔洛韦(治疗免疫功能正常或免疫功能低下的患者)或伐昔洛韦(治疗免疫功能正常的患者)在治疗带状疱疹方面有相似的疗效,并与阿昔洛韦在治疗首发或复发性生殖器疱疹(治疗免疫功能正常或免疫功能低下的患者)方面的疗效也同样相似。对于免疫功能正常的患者,泛昔洛韦对于抑制复发性生殖器疱疹和治疗口唇疱疹同样有效。

As such, famciclovir is a well tolerated first-line option for the treatment of herpes zoster and the treatment and suppression of genital herpes, and is approved for the treatment of recurrent orolabial herpes.Convenient patient-initiated single-day (for recurrent genital herpes) and single-dose (for orolabial herpes) dosage regimens may contribute to treatment compliance, patient acceptability and subsequent treatment outcomes.

因此,对于带状疱疹的治疗以及生殖器疱疹的抑制,泛昔洛韦是一种耐受性良好的首选药物,并已被批准用于治疗复发性口唇疱疹。该药物可以采用非常方便的单天(对于复发性生殖器疱疹)和单剂量(对于口唇疱疹)给药方案,这可能有助于提高患者的依从性、可接受性以及后续的治疗效果。

 

 

Dene Simpson et.alAdis Data Information BV. All rights reserved2006; Vol. 66 (18), pp. 2397-416.